Home » Newsletters » BioWorld

BioWorld

Dec. 4, 1991

View Archived Issues

BLOCKED RICIN TARGETS CANCER

MEDIMMUNE, MERCK COMPLETE DEAL

GENENTECH LICENSES CAMBRIDGE'S HIV PROTEIN

CAL BIO TO TAKE $6 MILLION CHARGE

ITALY APPROVES BTGC's GROWTH HORMONE

GENSIA SUBSIDIARY GETS TWO ANDAs

IVAX RAISES $110.5 MILLION IN PRIVATE OFFERING

FIELD STUDY GUIDELINES DUE

MARKER GENE REMOVED FROM ALTERED PLANTS

NICOTINE PATCH BATTLE HEATS UP

COURT DEALS SETBACK TO KODAK ON PCR

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....